Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) Research & Development (2020 - 2025)

Historic Research & Development for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $9.1 million.

  • RxSight's Research & Development rose 251.19% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.9 million, marking a year-over-year increase of 1953.79%. This contributed to the annual value of $34.4 million for FY2024, which is 1829.89% up from last year.
  • According to the latest figures from Q3 2025, RxSight's Research & Development is $9.1 million, which was up 251.19% from $10.2 million recorded in Q2 2025.
  • RxSight's 5-year Research & Development high stood at $10.4 million for Q1 2025, and its period low was $5.4 million during Q3 2021.
  • For the 5-year period, RxSight's Research & Development averaged around $7.6 million, with its median value being $7.2 million (2023).
  • Over the last 5 years, RxSight's Research & Development had its largest YoY gain of 2909.13% in 2021, and its largest YoY loss of 730.91% in 2021.
  • Over the past 5 years, RxSight's Research & Development (Quarter) stood at $5.9 million in 2021, then rose by 12.93% to $6.7 million in 2022, then rose by 9.88% to $7.3 million in 2023, then grew by 25.42% to $9.2 million in 2024, then decreased by 1.6% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $10.2 million for Q2 2025, and $10.4 million during Q1 2025.